NeuroSense director reports initial share holdings
NeuroSense Therapeutics Ltd. director Mandil-Levin Revital filed an initial ownership report showing option and share holdings in the company.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
NeuroSense Therapeutics Ltd. director Mandil-Levin Revital filed an initial ownership report showing option and share holdings in the company. The filing lists options to purchase 72,000 Ordinary Shares at an exercise price of $1.43 per share, expiring on March 10, 2032, which are fully vested and exercisable.
The report also shows direct ownership of several blocks of Ordinary Shares, including 52,526 shares, 60,000 shares, and 76,844 restricted shares. Certain restricted shares vest on December 30, 2026 and January 30, 2027, subject to continued service and potential acceleration upon achieving specified business milestones.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Mandil-Levin Revital
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Options to Purchase Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Options to Purchase Ordinary Shares — 72,000 contracts (Direct);
Ordinary Shares — 189,370 shares (Direct)
Footnotes (4)
- F1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's 2018 Share Incentive Plan must be registered in the name of a trustee.
- F2. These restricted shares vest on December 30, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person.
- F3. These restricted shares vest on January 30, 2027, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person.
- F4. These options are fully vested and exercisable.
Key Figures
Options granted: 72,000 options
Option exercise price: $1.43 per share
Option expiration: March 10, 2032
+5 more
8 metrics
Options granted
72,000 options
Options to purchase Ordinary Shares, fully vested and exercisable
Option exercise price
$1.43 per share
Exercise price for options on 72,000 Ordinary Shares
Option expiration
March 10, 2032
Expiration date of options to purchase Ordinary Shares
Ordinary Shares holding
52,526 shares
Direct Ordinary Shares reported following transaction
Additional Ordinary Shares
60,000 shares
Direct Ordinary Shares reported following transaction
Restricted shares
76,844 shares
Restricted Ordinary Shares subject to vesting conditions
Restricted vesting date 1
December 30, 2026
Restricted shares vest date, subject to continued service and milestones
Restricted vesting date 2
January 30, 2027
Restricted shares vest date, subject to continued service and milestones
Key Terms
Form 3, restricted shares, Section 102 of the Israeli Tax Ordinance, 2018 Share Incentive Plan, +2 more
6 terms
Form 3 regulatory
"INSIDER FILING DATA (Form 3):"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
Section 102 of the Israeli Tax Ordinance regulatory
"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued"
vest financial
"These restricted shares vest on January 30, 2027, subject to the Reporting Person's continued service"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
fully vested and exercisable financial
"These options are fully vested and exercisable."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the NeuroSense Therapeutics (NRSN) Form 3 filing show for Mandil-Levin Revital?
The Form 3 filing shows Mandil-Levin Revital’s initial ownership in NeuroSense Therapeutics, including options and ordinary shares. It records existing positions rather than new trades, helping investors understand the director’s equity alignment and outstanding equity awards with specific terms and vesting conditions.
How many options does Mandil-Levin Revital hold in NeuroSense Therapeutics (NRSN)?
Mandil-Levin Revital holds options to purchase 72,000 Ordinary Shares of NeuroSense Therapeutics. These options carry an exercise price of $1.43 per share and expire on March 10, 2032, and are described as fully vested and exercisable under the company’s equity incentive arrangements.
What are the key terms of Mandil-Levin Revital’s options in NeuroSense Therapeutics (NRSN)?
The options allow purchase of 72,000 Ordinary Shares at an exercise price of $1.43 per share, with an expiration date of March 10, 2032. Footnotes state that these options are fully vested and exercisable, reflecting a long-dated, already-earned equity incentive position.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates